Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
3期
已完成
NCT03025308
| 适应症 | Rheumatoid Arthritis |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Alfasigma S.p.A. |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 2,731 人 |
|---|
| 干预（药物） | Filgotinib, Placebo to match filgotinib |
|---|
| 开始日期 | 2017年2月28日 |
|---|
| 完成日期 | 2025年5月16日 |
|---|
| 结果公布日 | 2026年7月27日 |
|---|
摘要
The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the parent studies of filgotinib in rheumatoid arthritis (RA).
Number of Participants Who Reported Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Day 1 to Week 376 (end of study) · Participants
| Filgotinib 200 mg: With Prior Filgotinib Exposure | 1071 Participants |
|---|
| Filgotinob 200 mg: Without Prior Filgotinob Exposure | 300 Participants |
|---|
| Filgotinib 100 mg: With Prior Filgotinib Exposure | 769 Participants |
|---|
| Filgotinib 100 mg: Without Prior Filgotinib Exposure | 283 Participants |
|---|
| Filgotinib 200 mg: With Prior Filgotinib Exposure | 288 Participants |
|---|
| Filgotinob 200 mg: Without Prior Filgotinob Exposure | 74 Participants |
|---|
Number of Participants Who Reported Treatment-Emergent Graded Laboratory Abnormalities in Serum Chemistry Parameters
Day 1 to Week 376 (end of study) · Participants
| Filgotinib 200 mg: With Prior Filgotinib Exposure | 394 Participants |
|---|
| Filgotinob 200 mg: Without Prior Filgotinob Exposure | 98 Participants |
|---|
| Filgotinib 100 mg: With Prior Filgotinib Exposure | 274 Participants |
|---|
| Filgotinib 100 mg: Without Prior Filgotinib Exposure | 106 Participants |
|---|
| Filgotinib 200 mg: With Prior Filgotinib Exposure | 49 Participants |
|---|
| Filgotinob 200 mg: Without Prior Filgotinob Exposure | 16 Participants |
|---|
Number of Participants Who Reported Treatment-Emergent Graded Laboratory Abnormalities in Hematology Parameters
Day 1 to Week 376 (end of study) · Participants
| Filgotinib 200 mg: With Prior Filgotinib Exposure | 247 Participants |
|---|
| Filgotinob 200 mg: Without Prior Filgotinob Exposure | 60 Participants |
|---|
| Filgotinib 100 mg: With Prior Filgotinib Exposure | 165 Participants |
|---|
| Filgotinib 100 mg: Without Prior Filgotinib Exposure | 60 Participants |
|---|
| Filgotinib 200 mg: With Prior Filgotinib Exposure | 86 Participants |
|---|
| Filgotinob 200 mg: Without Prior Filgotinob Exposure | 29 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。